# Ophthalmology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Georgia O'Keeffe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET011-SYN-TD
- Date: 1968-03-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Yuki Tanabe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Wendell Ashby, MD

## Reason for consultation

New distortion and a central blurred spot in the left eye of an 80-year-old painter, suspicious for neovascular age-related macular degeneration. Please evaluate this week and treat as indicated. **S**

## History

Ms. O'Keeffe is seen at the request of Dr. Ashby two days after her primary care visit. Over the past few weeks straight lines on her canvases and door frames have looked bent with the left eye, and small print and fine color differences have become hard to judge. The right eye seems unchanged. She has had no eye pain, redness, flashes, or new floaters. She takes no medicines and no blood thinners. She paints daily, drives short routes by day, and is afraid of losing the central vision she needs for her work. **S**

## Examination

| System | Finding |
|---|---|
| Visual acuity | Best-corrected 78 letters right and 55 letters left |
| Intraocular pressure | 15 mmHg right and 16 mmHg left before injection |
| Anterior segment | Quiet in both eyes |
| Dilated fundus, left eye | Gray-green subretinal lesion under the fovea with surrounding fluid; large drusen |
| Dilated fundus, right eye | Large drusen and pigment changes; no fluid or hemorrhage |
| OCT | Left eye: subretinal fluid, central subfield thickness 418 µm. Both eyes: large drusen |
| After injection, left eye | Optic nerve head perfused; counts fingers; no pain |

BP 130/72 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 97% on room air; weight 56 kg; BMI 20.6 kg/m². All vital signs are synthetic.

## Data reviewed

Today's optical coherence tomography of both maculae, best-corrected acuity and pressures, and the primary care Amsler grid findings and acuity from two days ago. Best-corrected visual acuity, right eye (ETDRS letters): 78 (low); Best-corrected visual acuity, left eye (ETDRS letters): 55 (low); Central subfield thickness by OCT, left eye: 418 um (high); Intraocular pressure, right eye: 15 mmHg; Intraocular pressure, left eye: 16 mmHg. All results are synthetic.

## Assessment

1. **Neovascular age-related macular degeneration, left eye, active** (H35.3221). Confirmed clinically. A subfoveal gray-green lesion with subretinal fluid on OCT (central subfield thickness 418 µm) and acuity of 55 letters fit active choroidal neovascularization. The picture is typical, so treatment began today on OCT and fundus findings without fluorescein or OCT angiography; angiography is held in reserve if the response to loading is poor or the picture becomes atypical. The first intravitreal aflibercept 2 mg injection was given today without complication. **S**
2. **Intermediate dry age-related macular degeneration, right eye** (H35.3112). Large drusen and pigment changes without fluid or hemorrhage. This eye is at risk of conversion and now carries most of her reading and driving vision, so the AREDS2 supplement is indicated. **S**
3. **Visual function and safety**. She has trouble with small print and fine color judgment but remains independent. Right-eye acuity of 78 letters supports short local daytime driving for now, pending a formal driving assessment. Her mood is steady, but vision loss raises the risk of depression. **S**

## Recommendations

1. Intravitreal aflibercept 2 mg in the left eye every four weeks for three loading doses, then treat-and-extend by two-week steps while the macula stays dry; first dose given today.
2. At each injection visit: best-corrected acuity, OCT, intraocular pressure, and dilated examination of the right eye.
3. Fluorescein or OCT angiography only if the response to loading is poor or the findings become atypical.
4. AREDS2 supplement daily for the right eye (vitamin C, vitamin E, lutein, zeaxanthin, zinc, and copper; no beta-carotene), started today.
5. Daily Amsler grid checks of each eye in turn, with a same-day call for any new distortion or blur in either eye.
6. Call the same day for eye pain, increasing redness, worsening vision, light sensitivity, or a curtain over the vision; large-print instructions given.
7. Low-vision rehabilitation, with a home fall-risk review and a formal driving assessment; referral sent today. Until then, short local daytime routes only.
8. Repeat the PHQ-2 at the next primary care review.

## Strengths and supports

- Supports: a studio assistant, a housekeeper, and a sister who calls weekly; drives only short distances by day **S**

## Communication

Letter to Dr. Ashby today. The diagnosis, the injection schedule, and the warning signs were discussed with the patient, who agreed to treatment. **S**

## Follow-up

Retina clinic in four weeks for acuity, OCT, pressure, and the second injection, and at each injection visit after that. Primary care will repeat the PHQ-2 and review the rehabilitation and driving outcome at the first treat-and-extend visit. **S**

## Guideline basis

- Age-Related Macular Degeneration Preferred Practice Pattern (2024), American Academy of Ophthalmology
- CMID: Clinical Monitoring Intelligence Database, cataract and glaucoma monographs (eye-examination items) (2026), Aether Forge
